Proprietary Chinese medicine collection is coming! Analysis of the competition pattern of overlapping varieties of regional collection and national harvesting!

On September 9, Hubei Pharmaceutical Price and Bidding Procurement Management Service Network released the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.

On September 9, Hubei Pharmaceutical Price and Bidding Procurement Management Service Network released the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.

Chemical drugs and biological products shall be carried out by the joint procurement office of centralized drug procurement and use of drugs organized by the state on behalf of public medical institutions and socially-run medical institutions in various regions, and the Shanghai Municipal Pharmaceutical Centralized Bidding and Procurement Office shall undertake the daily work and implement it specifically; The procurement of the National Proprietary Chinese Medicine Alliance is carried out by the National Proprietary Chinese Medicine Joint Procurement Office, under the guidance of the National Medical Security Bureau, on behalf of the centralized procurement of proprietary Chinese medicines and related drugs, and the Hubei Provincial Medical Security Bureau undertakes the daily work of the Joint Procurement Office and is responsible for the specific implementation

Since the Hubei Alliance, the Guangdong Alliance and the Shandong Province have started the collection and collection of proprietary Chinese medicines, the price and reporting of varieties that coincide with regional collection and national mining have attracted much attention

The collection and procurement coexistence mode has been started to be solvedThe collection and mining coexistence mode has been started to be solved

The National Joint Procurement Office of Proprietary Chinese Medicines is composed of representatives appointed from Hubei, Beijing, Tianjin, Hebei, Shanxi, Inner Mongolia, Liaoning, Jilin, Heilongjiang, Shanghai, Jiangsu, Zhejiang, Anhui, Jiangxi, Shandong, Henan, Guangdong, Guangxi, Hainan, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, Gansu, Qinghai, Ningxia, Xinjiang, Xinjiang Production and Construction Corps and other alliance regions, and does not cover Hunan and Fujian, and is likely to be collected

The Hubei Interprovincial Alliance of Proprietary Chinese Medicine, launched in September 2021, includes Hubei, Hebei, Shanxi, Inner Mongolia, Liaoning, Fujian, Jiangxi, Henan, Hunan, Hainan, Chongqing, Sichuan, Guizhou, Tibet, Shaanxi, Gansu, Ningxia, Xinjiang and Xinjiang Production and Construction Corps

In the first half of 2022, Guangdong Alliance Qingkailing and other proprietary Chinese medicines involved Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai, and the results

On September 9, 2022, Shandong issued the Notice on the Third Batch of Drugs (Special Projects for Chinese Proprietary Medicines) in Shandong Province on Centralized Procurement Quotations, Decryption and Other Simulated Operations, which means that the collection of proprietary Chinese medicines in Shandong is still in

After the procurement of the National Proprietary Chinese Medicine Alliance was launched, the industry was concerned about: In what way will the above-mentioned launched collection of proprietary Chinese medicines coexist? The relevant rules
are still to be issued by the provinces.

After the procurement of the National Proprietary Chinese Medicine Alliance was launched, the industry was concerned about: In what way will the above-mentioned launched collection of proprietary Chinese medicines coexist? The relevant rules
are still to be issued by the provinces.

The price of coincident symbols may fall again

The price of the coincident may drop againThe price of the coincident may drop againThe price of the coincident may drop again

The National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 [2022]) mentions a total of 16 procurement groups grouped by "product-drug route", and none of the 16 procurement groups coincides
with the product procurement group of the Hubei Proprietary Chinese Medicine Interprovincial Alliance.
However, the National Proprietary Chinese Medicine Alliance Procurement Group 2 "Compound Thrombosis - Oral" has won the bid in the centralized procurement of proprietary Chinese medicines such as Qingkailing of Guangdong Alliance, and has also entered the centralized procurement
of the third batch of drugs (proprietary Chinese medicine special) in Shandong Province, which has been started but has not yet been quoted.

The National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 [2022]) mentions a total of 16 procurement groups grouped by "product-drug route", and none of the 16 procurement groups coincides
with the product procurement group of the Hubei Proprietary Chinese Medicine Interprovincial Alliance.
However, the National Proprietary Chinese Medicine Alliance Procurement Group 2 "Compound Thrombosis - Oral" has won the bid in the centralized procurement of proprietary Chinese medicines such as Qingkailing of Guangdong Alliance, and has also entered the centralized procurement
of the third batch of drugs (proprietary Chinese medicine special) in Shandong Province, which has been started but has not yet been quoted.

For the "compound thrombosis - oral" products, in the Guangdong Alliance Qingkailing and other proprietary Chinese medicine centralized procurement has just experienced price reductions, but also to face Shandong according to the enterprise representative product declaration price, the proportion of total days taken by enterprise products, product quality and safety and other factors for comprehensive review of the rules, but also to face the national proprietary Chinese medicine alliance procurement price
reduction.

For the "compound thrombosis - oral" products, in the Guangdong Alliance Qingkailing and other proprietary Chinese medicine centralized procurement has just experienced price reductions, but also to face Shandong according to the enterprise representative product declaration price, the proportion of total days taken by enterprise products, product quality and safety and other factors for comprehensive review of the rules, but also to face the national proprietary Chinese medicine alliance procurement price
reduction.

If the procurement of the National Proprietary Chinese Medicine Alliance continues the rules of the Hubei Interprovincial Alliance of Chinese Medicine, then the probability will be that the product group is divided into A and B units
.
Finally, the finalists are determined based on the sum of 60% of the price competition score and 40% of the technical evaluation score
.
Among them, the price competition score is that the declaring enterprise declares the price according to the quoted representative product, and determines the price competition score
through the reduction of the declared price.
The high probability of the selection rule is to rank the quotation reduction of all A competition units in the 16 product groups from high to low, and the top 70% of the enterprises with the decline rate (rounded round, the same below) will be eligible for the selection; If the last place is reduced by the same amount, it will be eligible for
the proposed selection.
The enterprises after the decline of 30% enter the bargaining process, accept the median reduction of all A competition units in the 16 product groups (50% of the reduction, the same below), and obtain the qualification
for the proposed selection.

If the procurement of the National Proprietary Chinese Medicine Alliance continues the rules of the Hubei Interprovincial Alliance of Chinese Medicine, then the probability will be that the product group is divided into A and B units
.
Finally, the finalists are determined based on the sum of 60% of the price competition score and 40% of the technical evaluation score
.
Among them, the price competition score is that the declaring enterprise declares the price according to the quoted representative product, and determines the price competition score
through the reduction of the declared price.
The high probability of the selection rule is to rank the quotation reduction of all A competition units in the 16 product groups from high to low, and the top 70% of the enterprises with the decline rate (rounded round, the same below) will be eligible for the selection; If the last place is reduced by the same amount, it will be eligible for
the proposed selection.
The enterprises after the decline of 30% enter the bargaining process, accept the median reduction of all A competition units in the 16 product groups (50% of the reduction, the same below), and obtain the qualification
for the proposed selection.

The benchmark price of the Hubei Interprovincial Alliance of Proprietary Chinese Medicines is the lowest winning bid/hanging net price of all products of the declaring enterprise as of the date of the procurement announcement (excluding the hanging net price of the Guangdong Provincial Procurement Platform and the selected price of centralized procurement of drugs in various provinces).

。 Therefore, the selected price of the centralized procurement of proprietary Chinese medicines such as Qingkailing of the Guangdong Alliance and the selected price of the third batch of drugs (proprietary Chinese medicines) in Shandong Province (special items for proprietary Chinese medicines) may not be collected by the National Proprietary Chinese Medicines Alliance, but if the Guangdong Alliance (Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai) and provinces outside Shandong link the Guangdong Alliance Qingkailing and other proprietary Chinese medicines centralized procurement and the third batch of drugs (proprietary Chinese medicines) in Shandong Province (special items for proprietary Chinese medicines) The selected price of centralized quantity procurement, then "compound thrombosis - oral.
" "There is a risk
that the price will fall again and again to win the bid.
"

The benchmark price of the Hubei Interprovincial Alliance of Proprietary Chinese Medicines is the lowest winning bid/hanging net price of all products of the declaring enterprise as of the date of the procurement announcement (excluding the hanging net price of the Guangdong Provincial Procurement Platform and the selected price of centralized procurement of drugs in various provinces).

。 Therefore, the selected price of the centralized procurement of proprietary Chinese medicines such as Qingkailing of the Guangdong Alliance and the selected price of the third batch of drugs (proprietary Chinese medicines) in Shandong Province (special items for proprietary Chinese medicines) may not be collected by the National Proprietary Chinese Medicines Alliance, but if the Guangdong Alliance (Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai) and provinces outside Shandong link the Guangdong Alliance Qingkailing and other proprietary Chinese medicines centralized procurement and the third batch of drugs (proprietary Chinese medicines) in Shandong Province (special items for proprietary Chinese medicines) The selected price of centralized quantity procurement, then "compound thrombosis - oral.
" "There is a risk
that the price will fall again and again to win the bid.
"

The National Proprietary Chinese Medicine Alliance Procurement Group 4 "Hua Toad - Oral", the Procurement Group 5 "Elderberry - Oral", the Procurement Group 12 "Awakening Brain Jing - Injection", the Procurement Group 13 "Raven Bile Oil - Injection", also entered the third batch of drugs in Shandong Province (proprietary Chinese medicine special) centralized procurement product catalog, the above products may also face a drop
in price again and again.

The National Proprietary Chinese Medicine Alliance Procurement Group 4 "Hua Toad - Oral", the Procurement Group 5 "Elderberry - Oral", the Procurement Group 12 "Awakening Brain Jing - Injection", the Procurement Group 13 "Raven Bile Oil - Injection", also entered the third batch of drugs in Shandong Province (proprietary Chinese medicine special) centralized procurement product catalog, the above products may also face a drop
in price again and again.

The purchase volume of the winning varieties is guaranteed

The implementation of the procurement volume of the winning varieties guarantees the implementation of the procurement volume of the winning varieties and the implementation of the guarantee of the procurement volume of the winning varieties

In view of the fact that the basis of volume collection is based on the price of the reported quantity, the rules of centralized procurement of proprietary Chinese medicines such as Guangdong Alliance Qing Kailing promise that the incremental part of the selected product is that the medical institution chooses the procurement from the
winning enterprise.
If the winning bidder of the National Proprietary Chinese Medicine Alliance procurement is not the winning enterprise of the centralized procurement of proprietary Chinese medicines such as Guangdong Alliance Qingkailing, then it is possible that the incremental part of the original plan of Guangdong medical institutions will not choose the winning enterprise of Guangdong Alliance Qingkailing and other proprietary Chinese medicine centralized procurement, but choose the winning enterprise
of the National Proprietary Chinese Medicine Alliance procurement.

In view of the fact that the basis of volume collection is based on the price of the reported quantity, the rules of centralized procurement of proprietary Chinese medicines such as Guangdong Alliance Qing Kailing promise that the incremental part of the selected product is that the medical institution chooses the procurement from the
winning enterprise.
If the winning bidder of the National Proprietary Chinese Medicine Alliance procurement is not the winning enterprise of the centralized procurement of proprietary Chinese medicines such as Guangdong Alliance Qingkailing, then it is possible that the incremental part of the original plan of Guangdong medical institutions will not choose the winning enterprise of Guangdong Alliance Qingkailing and other proprietary Chinese medicine centralized procurement, but choose the winning enterprise
of the National Proprietary Chinese Medicine Alliance procurement.

According to the rules of the Hubei Interprovincial Alliance of Chinese Proprietary Medicines, if the products filled in by the pharmaceutical institution for procurement needs are in the selection range, the selected products with the highest reduction in the same bidding unit (calculated by the reduction of the shortlisted quotation, the same below) are distributed to the corresponding medical institutions according to the agreed procurement volume; Other selected products are distributed to the corresponding medical institutions
according to 90% of the agreed purchase volume.
The agreed purchase volume of the products that the pharmaceutical institution fills in the procurement demand but is not in the selected range, has not been declared by the enterprise, and the agreed purchase volume of the product with a production capacity of "0", and the agreed purchase volume that has not been allocated for the selected product is allocated as the amount to be distributed, and the pharmaceutical institution shall allocate the 30% of the amount to be allocated to the selected enterprise with the highest decline in the same product group; (2) The remaining 70% of the amount to be allocated is independently selected
by the medical institution from all the selected enterprise products.

According to the rules of the Hubei Interprovincial Alliance of Chinese Proprietary Medicines, if the products filled in by the pharmaceutical institution for procurement needs are in the selection range, the selected products with the highest reduction in the same bidding unit (calculated by the reduction of the shortlisted quotation, the same below) are distributed to the corresponding medical institutions according to the agreed procurement volume; Other selected products are distributed to the corresponding medical institutions
according to 90% of the agreed purchase volume.
The agreed purchase volume of the products that the pharmaceutical institution fills in the procurement demand but is not in the selected range, has not been declared by the enterprise, and the agreed purchase volume of the product with a production capacity of "0", and the agreed purchase volume that has not been allocated for the selected product is allocated as the amount to be distributed, and the pharmaceutical institution shall allocate the 30% of the amount to be allocated to the selected enterprise with the highest decline in the same product group; (2) The remaining 70% of the amount to be allocated is independently selected
by the medical institution from all the selected enterprise products.

A and B competitive units are all selected enterprises, if the provinces do not distinguish between A and B competitive units when actually procuring, then the pharmaceutical institutions may not necessarily purchase
according to the procurement results of the competitive units.

A and B competitive units are all selected enterprises, if the provinces do not distinguish between A and B competitive units when actually procuring, then the pharmaceutical institutions may not necessarily purchase
according to the procurement results of the competitive units.

Taking biological products as an example, the National Organization Drug Joint Procurement Office issued the "National Drug Centralized Procurement Document (Insulin Special Project) (GYYD2021-3)", mentioning that on the basis of giving priority to the use of the selected products in the centralized procurement of drugs, the remaining amount can be in accordance with the relevant provisions of the local centralized procurement management of drugs, and other products with appropriate prices can be purchased; And according to the results of the price reduction, it is divided into Class A, Class B, and Class
C.
However, the final winning bid results did not show Category A, Category B and Category C, so when the actual implementation was carried out, some medical institutions in individual provinces gave priority to purchasing the original research products rather than the winning products with the highest decline, and the purchase volume of the winning products may not be guaranteed
.

Taking biological products as an example, the National Organization Drug Joint Procurement Office issued the "National Drug Centralized Procurement Document (Insulin Special Project) (GYYD2021-3)", mentioning that on the basis of giving priority to the use of the selected products in the centralized procurement of drugs, the remaining amount can be in accordance with the relevant provisions of the local centralized procurement management of drugs, and other products with appropriate prices can be purchased; And according to the results of the price reduction, it is divided into Class A, Class B, and Class
C.
However, the final winning bid results did not show Category A, Category B and Category C, so when the actual implementation was carried out, some medical institutions in individual provinces gave priority to purchasing the original research products rather than the winning products with the highest decline, and the purchase volume of the winning products may not be guaranteed
.
Relevant provisions on procurement management, appropriate procurement of other products at reasonable prices; And according to the results of the price reduction, it is divided into Class A, Class B, and Class
C.
However, the final winning bid results did not show Category A, Category B and Category C, so when the actual implementation was carried out, some medical institutions in individual provinces gave priority to purchasing the original research products rather than the winning products with the highest decline, and the purchase volume of the winning products may not be guaranteed
.

It can be seen that the collection rules of proprietary Chinese medicines are more conducive to manufacturers
with good price management and brand advantages in the past.

It can be seen that the collection rules of proprietary Chinese medicines are more conducive to manufacturers
with good price management and brand advantages in the past.

Non-TCM Approved Natural Medicines were selected

Non-Chinese Medicine Approval Natural Medicines were selected as Non-Chinese Medicine Approved Natural Medicines Selected as Non-Chinese Medicine Approved Natural Medicines

The National Proprietary Chinese Medicine Alliance Procurement Group also includes products that are not approved by proprietary Chinese medicines but are natural medicines, such as Purchasing Group 14 "Ginkgo Biloba - Injection" and Procurement Group 15 "Ginkgo Biloba Extract - Injection"
.
This means that the products of natural medicines, even if they are chemical drug approvals, will enter the collection
of proprietary Chinese medicines in the future.

The National Proprietary Chinese Medicine Alliance Procurement Group also includes products that are not approved by proprietary Chinese medicines but are natural medicines, such as Purchasing Group 14 "Ginkgo Biloba - Injection" and Procurement Group 15 "Ginkgo Biloba Extract - Injection"
.
This means that the products of natural medicines, even if they are chemical drug approvals, will enter the collection
of proprietary Chinese medicines in the future.

Products that are not selected are included in the monitoring and management

Products that are not selected are included in monitoring managementNot selected products are included in monitoring management

According to the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 of 2022)", during the procurement cycle, the unselected products are included in the monitoring and management of the alliance area, and the procurement of unselected products by medical institutions shall not exceed 10%
of the actual procurement volume of the same procurement group.
Under this limitation, in order to survive and develop, enterprises with larger market sizes will face a price war in order to win the bid, and the greater
the pressure to reduce prices.

According to the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 of 2022)", during the procurement cycle, the unselected products are included in the monitoring and management of the alliance area, and the procurement of unselected products by medical institutions shall not exceed 10%
of the actual procurement volume of the same procurement group.
Under this limitation, in order to survive and develop, enterprises with larger market sizes will face a price war in order to win the bid, and the greater
the pressure to reduce prices.